All articles by Phillip Broadwith – Page 13
-
Business
Environmental research goes private
Exclusive interview with Fera chief Hilary Aldridge as the UK’s Food and Environment Research Agency becomes majority-owned by Capita
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
Business
BASF introduces bio-based polyTHF
Process uses 1,4-butanediol from microbial digestion of sugar feedstocks to make component of polyester and polyurethane materials
-
Business
Mallinckrodt to buy Ikaria to expand in US hospitals
$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
Business
AstraZeneca to spin off anti-infectives research
Early-stage research will transfer to a new company, while AZ and MedImmune retain late-stage programmes
-
Business
Asahi Kasei to buy Polypore for battery materials
$2.2bn deal adds to Japanese consolidation in energy storage
-
Business
Catalytic carbon dioxide convertors
Company profile: Econic Technologies makes catalysts that build carbon dioxide into performance polymers
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Europe approves stem cell therapy
Treatment for burn-damaged eyes uses patient’s own scaffold-grown cells
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
Business
Teva wins generic esomeprazole race
US approval of heartburn drug after Ranbaxy version was withdrawn by regulators
-
Business
US approves internal tissue glue
Urethane-based TissuGlu aids healing after abdominal surgery
-
Business
Fatal blast at Indian chemical plant
One worker killed and four injured at Survival Technologies plant in Ankleshwar
-
Business
UK calls for fracking restrictions
Environment committee wants to protect national parks and tighten regulation
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
Business
Biogen Idec to buy Convergence for pain pipeline
UK firm will remain intact as a ‘centre of excellence’ in pain R&D for Biogen
-
Business
EU recommends Parkinson’s drug for approval
First new molecule for a decade, but Alzheimer’s still posing challenges as antibody treatment withdrawn from trials